Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Precision BioSciences priced an underwritten public offering of approximately 10.2 million shares and 5.9 million pre-funded warrants for gross proceeds of $125 million. The offering included participation from several life sciences investors including First Light Asset Management and MPM BioImpact. Proceeds will fund research and development for PBGENE-HBV and PBGENE-DMD programs.
Sylvamo has entered into a put option agreement for a binding offer to sell its Europe business to Midas Atlantic Partners in partnership with The Najafi Companies. The transaction includes uncoated freesheet paper mills in France and Sweden, with Sylvamo receiving the right to 20% of future distributions of the business in exchange for the transfer. The deal is expected to close by the end of Q1 2027 following mandatory consultations with works councils and employee representatives.
Starry Sea Acquisition M&A Deal with SuperiorMed Healthcare Group
Starry Sea Acquisition Corp (SSEA) deposited $60,000 into its trust account to extend the deadline for its business combination with SuperiorMed Healthcare Group from November 7, 2026, to December 7, 2026. The extension payment was funded via a loan from SuperiorMed Healthcare, an affiliate of the merger target.
Onconetix entered into a first amendment to its existing share exchange agreement with Realbotix Corp. to acquire Realbotix, LLC. The amendment modifies the ownership structure such that the seller will own 95% of the buyer if net cash is less than $12.5 million and extends the deal's outside closing date to March 31, 2027.
Eva Live Inc. announced the commercial launch of EvaXCrypto, an AI-powered cryptocurrency trading software platform that provides market analytics and automated trade execution. The platform supports live trading connectivity across major exchanges including Coinbase, Binance.US, and Kraken, and is intended to generate recurring software subscription revenue.
Tempest Therapeutics received a deficiency notice from Nasdaq on November 4, 2026, because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has until May 3, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. The notice has no immediate effect on the listing of the company's common stock.
Parabolic Technologies, Inc. closed a firm commitment underwritten public offering of 4,963,235 units at a price of $2.72 per unit, generating gross proceeds of approximately $13.5 million. Each unit consists of one share of Class A common stock (or a pre-funded warrant) and two warrants with an initial exercise price of $6.80. The company intends to use the net proceeds for working capital, general corporate purposes, and debt repayment.
Annovis Bio entered into an underwriting agreement to raise approximately $21.0 million through a public offering of 19,000,000 shares of common stock and 2,000,000 pre-funded warrants, accompanied by warrants to purchase an additional 21,000,000 shares. The company intends to use the proceeds for the clinical development of its lead compound, Buntanetap, in studies for Alzheimer’s and Parkinson’s disease.
Monroe Capital Asset-Backed Finance Company Capital Raise
Monroe Capital Asset-Backed Finance Company, LP issued 220 shares (Class-S and Class-I) and $220,000 in principal amount of 12.00% promissory notes to approximately 220 accredited investors. The company received aggregate net proceeds of $152,000 from the notes and approximately $5,592 from the equity shares. The transaction was conducted as a private placement to satisfy REIT-related administrative and capital requirements.
Chiron Real Estate Signs $173M M&A Deal with The Pinnacle North Bethesda
Chiron Real Estate Inc. completed the acquisition of The Pinnacle North Bethesda, a senior housing community in Maryland, for $173.2 million. This filing serves as an amendment to provide required audited financial statements and pro forma information for the acquired asset, which opened in June 2026. Management expects the property to reach stabilization with a yield-on-cost exceeding 7% by 2029.
BHAV Acquisition Corp II completed its initial public offering of 10,000,000 units at $10.00 per unit, raising $100 million in gross proceeds. Simultaneously, the company raised an additional $2.25 million through a private placement of 225,000 units to its sponsor, BHAV Partners II LLC. A total of $100.5 million ($10.05 per unit) was placed into a trust account to fund a future business combination.
Ani Pharmaceuticals Signs $676M M&A Deal with Egetis Therapeutics AB
ANI Pharmaceuticals announced a recommended public cash offer to acquire all outstanding shares, convertibles, and warrants of Sweden-based Egetis Therapeutics AB. To finance the acquisition and refinance existing debt, ANI entered into a $676 million 364-day senior bridge credit facility with JPMorgan Chase Bank. The offer price is set at SEK 11.25 per share in cash.
Lci Industries M&A Deal with Patrick Industries, Inc.
LCI Industries provided a status update on its pending merger with Patrick Industries, confirming that its board rejected a competing unsolicited proposal from Monomoy Capital. The company reaffirmed its commitment to the Patrick merger, noting that the registration statement for the transaction was declared effective by the SEC on October 19, 2026.
iSpecimen Signs $4.5M M&A Deal with Foldlab AI Ltd.
iSpecimen Inc. completed the acquisition of AI software assets from Foldlab AI Ltd. for an aggregate purchase price of $4.5 million, consisting of $750,000 in cash, $1.25 million in milestone payments, and $2.5 million in common stock. The acquired assets include a Disease-Associated Protein Discovery AI Agent and a Disease Trend Prediction and Monitoring AI Model, marking the company's entry into AI-powered drug discovery.
Nextera Energy M&A Deal with Dominion Energy, Inc.
NextEra Energy filed updated pro forma financial information regarding its pending acquisition of Dominion Energy, which was originally announced on May 15, 2026. Under the merger agreement, Dominion Energy shareholders will receive 0.8138 shares of NextEra common stock and a pro rata share of $360 million in cash. The filing serves to incorporate these financials into NextEra's registration statements as the companies work toward satisfying closing conditions.
Axon Enterprise Partnership with Skydio, Inc. Worth $1.2B
Axon Enterprise announced a $1.2 billion incremental investment in Skydio to increase its ownership stake from 15% to approximately 37% on a fully diluted basis. Alongside the investment, Axon becomes the exclusive distributor for Skydio drones to public safety agencies in the U.S. and Canada, significantly expanding their joint 'Drone as First Responder' (DFR) initiative.
Sunrise Realty Trust M&A Deal with Southern Realty Trust Inc.
Sunrise Realty Trust (SUNS) completed its merger with Southern Realty Trust (SRT), consolidating two Tannenbaum Capital Group affiliates into a single Nasdaq-listed commercial real estate lending platform. SRT stockholders received 1.45 shares of SUNS common stock plus $0.05 in cash per share, resulting in SUNS issuing approximately 8.46 million new shares. The combined company has a pro forma book value of approximately $285 million and total assets of $534 million.
Pantages Capital Acquisition Nasdaq/NYSE Compliance Notice
Pantages Capital Acquisition Corporation received an extension from Nasdaq to regain compliance with the Minimum Total Holders Requirement. The company has until March 1, 2027, to demonstrate it has at least 400 total holders of its Class A ordinary shares to avoid delisting.
CVR Energy issued and sold 10,515,248 shares of common stock at a public offering price of $47.55 per share, generating approximately $490 million in net proceeds. The company intends to use the funds to finance its acquisition of refineries from Marathon Petroleum Corporation and to redeem its outstanding 5.750% Senior Notes due 2028.
Essential Utilities M&A Deal with American Water Works Company, Inc.
Essential Utilities and American Water Works Company filed a Stipulation of Settlement with the New Jersey Board of Public Utilities (NJBPU) regarding their pending merger. The settlement was reached with all parties, including the NJBPU staff and the New Jersey Division of Rate Counsel, and is a key step toward obtaining regulatory approval for the transaction. The merger, originally announced in October 2025, will result in Essential Utilities becoming a wholly owned subsidiary of American Water.
Pacira BioSciences provided a status update on its pending acquisition by Viatris Inc., noting that the tender offer for $36.50 per share commenced on October 30, 2026. Due to the pending merger, the company will not release Q3 2026 earnings or hold a conference call, and it has withdrawn its previously issued 2026 financial guidance.
Transportation & Logistics Systems Signs $4.75M M&A Deal with Patriot Glass Solutions, LLC
Transportation and Logistics Systems, Inc. (TLSS) completed the acquisition of an 80% membership interest in Patriot Glass Solutions, LLC (PGS) and four related nanotechnology patents from Badcer Ops, Inc. The merger consideration consisted of 47,500 shares of Series J Senior Convertible Preferred Stock with an aggregate stated value of $4.75 million. Additionally, the company issued $351,800 in preferred stock to satisfy outstanding PGS promissory notes and expense advances.
BlackRock Monticello Debt Real Estate Investment Trust Capital Raise of $19.8M
BlackRock Monticello Debt Real Estate Investment Trust sold 783,564.3076 common shares in a continuous private offering for aggregate consideration of approximately $19.77 million. The sale included Class I, Class S, and Class E common shares and was conducted as an unregistered sale exempt under Regulation D.
Live Oak Bancshares, Inc. priced a public offering of 4,000,000 depositary shares, each representing a 1/40th interest in its 8.750% Fixed Rate Series B Non-Cumulative Perpetual Preferred Stock, at $25 per share. The company expects to raise $100 million in gross proceeds (excluding a 600,000 share overallotment option) to support balance sheet growth and enhance its capital position.
Vertical Data Inc. closed a $4.24 million private placement of 1,413,640 common shares at $3.00 per share to support a potential uplisting to a national securities exchange. The offering included significant participation from insiders, including CEO Deven Soni, and the company's placement agent, B. Riley Securities.
PSQ Holdings Divestiture to FreeHold Brands, LLC for $5.5M
PSQ Holdings completed the sale of its EveryLife direct-to-consumer baby products business to FreeHold Brands for $5.5 million in total consideration. The deal includes $1.0 million in cash and a $4.5 million secured seller note, marking the company's final transition to a pure-play fintech business focused on payments and consumer financing.
Beacon Topco M&A Deal with Clywedog Therapeutics, Inc.
Beacon Topco, Inc. entered into a third amendment to its merger agreement with Clywedog Therapeutics, Inc. and Barinthus Biotherapeutics plc. The amendment updates the expected closing timeline and extends the 'End Date' for the merger to November 13, 2026.
Parabilis Medicines entered into a lease amendment to expand its corporate headquarters in Cambridge, Massachusetts, by 33,525 square feet. The agreement also extends the existing lease term from March 2031 through December 2037 and includes options for two additional five-year extensions.
Somnigroup International M&A Deal with Leggett & Platt, Incorporated
Somnigroup International Inc. completed its acquisition of Leggett & Platt, Incorporated, which became a direct, wholly owned subsidiary. The transaction was structured as an all-stock merger where Leggett & Platt shareholders received 0.1455 shares of Somnigroup common stock for each share held. This filing serves as an amendment to provide required historical and pro forma financial statements following the closing of the deal.
Fate Therapeutics entered into a sales agreement with Leerink Partners to establish an at-the-market (ATM) offering program for up to $100 million of its common stock. The company is not obligated to sell any shares and will pay a commission of up to 3.0% on any gross proceeds. This program replaces a previous ATM facility that was terminated concurrently.